-$0.03 Earnings Per Share Expected for Clearside Biomedical, Inc. (NASDAQ:CLSD) This Quarter

Analysts expect Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) to post earnings per share (EPS) of ($0.03) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Clearside Biomedical’s earnings, with estimates ranging from ($0.12) to $0.23. Clearside Biomedical reported earnings per share of ($0.13) during the same quarter last year, which would indicate a positive year-over-year growth rate of 76.9%. The company is expected to issue its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Clearside Biomedical will report full year earnings of ($0.25) per share for the current financial year, with EPS estimates ranging from ($0.50) to $0.27. For the next financial year, analysts expect that the business will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.56) to ($0.33). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD – Get Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported $0.31 EPS for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.22. The business had revenue of $25.69 million during the quarter, compared to the consensus estimate of $13.16 million. Clearside Biomedical had a return on equity of 1.63% and a net margin of 1.27%. During the same period last year, the firm earned ($0.14) earnings per share.

CLSD has been the subject of a number of research reports. TheStreet upgraded Clearside Biomedical from a “d” rating to a “c” rating in a research note on Friday, April 8th. JMP Securities decreased their target price on Clearside Biomedical from $11.00 to $10.00 and set a “market outperform” rating for the company in a research note on Friday, March 11th. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Wednesday, April 13th. StockNews.com assumed coverage on Clearside Biomedical in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Wedbush restated an “outperform” rating and issued a $9.00 target price on shares of Clearside Biomedical in a research note on Friday, March 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Clearside Biomedical currently has a consensus rating of “Buy” and a consensus price target of $9.25.

NASDAQ:CLSD opened at $1.53 on Thursday. Clearside Biomedical has a one year low of $1.31 and a one year high of $7.73. The stock has a 50-day simple moving average of $1.98 and a 200 day simple moving average of $2.85.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Advisor Group Holdings Inc. raised its holdings in Clearside Biomedical by 26.4% during the third quarter. Advisor Group Holdings Inc. now owns 9,350 shares of the company’s stock worth $56,000 after purchasing an additional 1,950 shares in the last quarter. Citigroup Inc. lifted its position in Clearside Biomedical by 190.2% in the fourth quarter. Citigroup Inc. now owns 9,863 shares of the company’s stock worth $27,000 after purchasing an additional 6,464 shares during the period. PDT Partners LLC acquired a new stake in Clearside Biomedical in the fourth quarter worth approximately $29,000. Walleye Trading LLC acquired a new stake in Clearside Biomedical in the fourth quarter worth approximately $32,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Clearside Biomedical in the third quarter worth approximately $71,000. Institutional investors and hedge funds own 46.56% of the company’s stock.

Clearside Biomedical Company Profile (Get Rating)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

Featured Articles